Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (51 quarters reported)
$580M in Q2 2013 → $168M now. Hover for any quarter.
As reported for the quarter ended December 31, 2025. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Genedx Holdings Corp | 68.5% | Trimmed 0.6% | 884,654 | $115M |
| Ardelyx Inc | 6.5% | Added 25% | 1,872,624 | $10.9M |
| Biohaven Ltd | 5.2% | Added 4.4% | 772,181 | $8.72M |
| Teladoc Health Inc Call | 2.7% | Added 38% | 650,000 | $4.55M |
| Novavax Inc Call | 2.4% | New | 600,000 | $4.03M |
| Ardelyx Inc Call | 2.1% | Trimmed 5.2% | 600,000 | $3.5M |
| Quidelortho Corp | 2.0% | Unchanged | 118,291 | $3.38M |
| Forian Inc | 1.7% | Unchanged | 1,366,107 | $2.9M |
| Personalis Inc | 1.6% | Added 48% | 339,343 | $2.7M |
| Biohaven Ltd Call | 1.6% | Trimmed 15% | 232,900 | $2.63M |
| Teladoc Health Inc | 1.5% | Trimmed 50% | 354,338 | $2.48M |
| Taysha Gene Therapies Inc | 0.9% | New | 265,000 | $1.46M |
| Cava Group Inc | 0.6% | Unchanged | 17,100 | $1M |
| Edgewise Therapeutics Inc | 0.6% | New | 38,343 | $951K |
| DO Day One Biopharmaceuticals I | 0.6% | New | 100,000 | $932K |
| Pfizer Inc Call | 0.4% | New | 25,000 | $623K |
| AE Ark ETF Tr | 0.3% | New | 19,500 | $565K |
| Sangamo Therapeutics Inc | 0.3% | Added 3.1% | 1,035,742 | $435K |
| Biogen Inc | 0.3% | Unchanged | 2,412 | $424K |
| Tempus Ai Inc | 0.2% | New | 6,507 | $384K |
| Tesla Inc | 0.1% | Unchanged | 500 | $225K |
| HG Hertz Global Hldgs Inc | 0.0% | New | 15,000 | $77.1K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended December 31, 2025 · filed February 18, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Novavax Inc | Exited | −635,000 | −$5.51M | — |
| Palantir Technologies Inc | Exited | −29,500 | −$5.38M | — |
| Novavax Inc | New | +600,000 | +$4.03M | 2.4% |
| CD Centene Corp Del | Exited | −110,300 | −$3.94M | — |
| Teladoc Health Inc | Trimmed | −351,078 | −$2.46M | 1.5% |
| Ardelyx Inc | Added | +368,798 | +$2.15M | 6.5% |
| Novavax Inc | Exited | −243,000 | −$2.11M | — |
| Taysha Gene Therapies Inc | New | +265,000 | +$1.46M | 0.9% |
| Teladoc Health Inc | Added | +179,500 | +$1.26M | 2.7% |
| Edgewise Therapeutics Inc | New | +38,343 | +$951K | 0.6% |
Showing the 10 largest of 23 changes.
quarter ended September 30, 2025 · filed November 19, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Genedx Holdings Corp | Exited | −100,000 | −$9.23M | — |
| Springworks Therapeutics Inc | Exited | −150,000 | −$7.05M | — |
| Novavax Inc | New | +635,000 | +$5.51M | 3.4% |
| CD Centene Corp Del | New | +110,300 | +$3.94M | 2.5% |
| Genedx Holdings Corp | Trimmed | −32,500 | −$3.5M | 59.9% |
| Ardelyx Inc | Trimmed | −547,000 | −$3.01M | 2.2% |
| Teladoc Health Inc | Added | +324,416 | +$2.51M | 3.4% |
| Teladoc Health Inc | Trimmed | −279,600 | −$2.16M | 2.3% |
| Novavax Inc | New | +243,000 | +$2.11M | 1.3% |
| Personalis Inc | New | +229,435 | +$1.5M | 0.9% |
Showing the 10 largest of 18 changes.
quarter ended June 30, 2025 · filed August 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Springworks Therapeutics Inc | Exited | −531,351 | −$23.4M | — |
| SS SPDR Ser Tr | Exited | −280,000 | −$22.7M | — |
| Genedx Holdings Corp | New | +100,000 | +$9.23M | 6.3% |
| Viking Therapeutics Inc | Exited | −336,700 | −$8.13M | — |
| Springworks Therapeutics Inc | New | +150,000 | +$7.05M | 4.8% |
| Teladoc Health Inc | Added | +605,800 | +$5.28M | 4.5% |
| Genedx Holdings Corp | Trimmed | −47,500 | −$4.38M | 58.4% |
| Ardelyx Inc | Trimmed | −973,710 | −$3.82M | 3.8% |
| Peloton Interactive Inc | Exited | −500,000 | −$3.16M | — |
| Teladoc Health Inc | Trimmed | −184,900 | −$1.61M | 2.3% |
Showing the 10 largest of 14 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Ser Tr | New | +280,000 | +$22.7M | 11.5% |
| SS Select Sector SPDR Tr | Exited | −115,000 | −$15.8M | — |
| Springworks Therapeutics Inc | Added | +276,578 | +$12.2M | 11.8% |
| Viking Therapeutics Inc | New | +336,700 | +$8.13M | 4.1% |
| Genedx Holdings Corp | Trimmed | −53,514 | −$4.74M | 43.3% |
| Teladoc Health Inc | New | +565,900 | +$4.5M | 2.3% |
| Biohaven Ltd | Trimmed | −185,825 | −$4.47M | 8.1% |
| Biocryst Pharmaceuticals Inc | Exited | −535,558 | −$4.03M | — |
| Novavax Inc | Exited | −466,000 | −$3.75M | — |
| Peloton Interactive Inc | New | +500,000 | +$3.16M | 1.6% |
Showing the 10 largest of 20 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS Select Sector SPDR Tr | New | +115,000 | +$15.8M | 8.6% |
| SS SPDR Ser Tr | Exited | −100,000 | −$9.88M | — |
| Springworks Therapeutics Inc | Added | +220,573 | +$7.97M | 5.0% |
| Biohaven Ltd | Added | +146,520 | +$5.47M | 17.3% |
| Phathom Pharmaceuticals Inc | Trimmed | −604,423 | −$4.91M | 0.6% |
| Biohaven Ltd | Trimmed | −102,700 | −$3.84M | 4.1% |
| Myriad Genetics Inc | Exited | −134,500 | −$3.68M | — |
| Ardelyx Inc | Added | +720,231 | +$3.65M | 5.8% |
| Phathom Pharmaceuticals Inc | Exited | −192,700 | −$3.48M | — |
| EP Eyepoint Pharmaceuticals Inc | Exited | −350,000 | −$2.8M | — |
Showing the 10 largest of 20 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR Ser Tr | New | +100,000 | +$9.88M | 5.9% |
| Phathom Pharmaceuticals Inc | Added | +524,487 | +$9.48M | 8.1% |
| Biohaven Ltd | Added | +187,700 | +$9.38M | 9.1% |
| Novavax Inc | New | +534,600 | +$6.75M | 4.0% |
| Springworks Therapeutics Inc | Trimmed | −199,000 | −$6.38M | 0.7% |
| Phathom Pharmaceuticals Inc | New | +192,700 | +$3.48M | 2.1% |
| Genedx Holdings Corp | Trimmed | −60,000 | −$2.55M | 26.6% |
| Myriad Genetics Inc | Added | +74,500 | +$2.04M | 2.2% |
| Palantir Technologies Inc | Trimmed | −50,000 | −$1.86M | 0.4% |
| Myriad Genetics Inc | Exited | −74,500 | −$1.82M | — |
Showing the 10 largest of 20 changes.
quarter ended June 30, 2024 · filed August 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Walgreens Boots Alliance Inc | Exited | −410,000 | −$8.89M | — |
| Springworks Therapeutics Inc | Trimmed | −188,383 | −$7.1M | 8.2% |
| Ardelyx Inc | Trimmed | −551,569 | −$4.09M | 10.3% |
| Biohaven Ltd | Trimmed | −104,400 | −$3.62M | 22.7% |
| EP Eyepoint Pharmaceuticals Inc | Added | +409,500 | +$3.56M | 3.6% |
| SS SPDR Ser Tr | Exited | −35,000 | −$3.32M | — |
| Phathom Pharmaceuticals Inc | New | +225,000 | +$2.32M | 2.2% |
| EP Eyepoint Pharmaceuticals Inc | Trimmed | −230,000 | −$2M | 1.9% |
| Myriad Genetics Inc | New | +74,500 | +$1.82M | 1.7% |
| Myriad Genetics Inc | New | +60,000 | +$1.47M | 1.4% |
Showing the 10 largest of 28 changes.
quarter ended March 31, 2024 · filed May 15, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Teladoc Health Inc | Exited | −639,600 | −$13.8M | — |
| Springworks Therapeutics Inc | Added | +264,500 | +$13M | 13.8% |
| Quidelortho Corp | Exited | −172,100 | −$12.7M | — |
| Springworks Therapeutics Inc | Trimmed | −207,100 | −$10.2M | 1.4% |
| Genedx Holdings Corp | Added | +948,253 | +$8.66M | 6.8% |
| Ardelyx Inc | Added | +1,175,000 | +$8.58M | 9.9% |
| Ardelyx Inc | Trimmed | −1,154,100 | −$8.42M | 1.3% |
| Walgreens Boots Alliance Inc | Added | +310,000 | +$6.72M | 5.9% |
| PB Pacific Biosciences Calif In | Trimmed | −1,537,100 | −$5.76M | 0.6% |
| Biohaven Ltd | Added | +88,423 | +$4.84M | 29.2% |
Showing the 10 largest of 29 changes.
Loading...
